Inmune Bio, Inc. (INMB) Insider Trading Disclosures
Inmune Bio, Inc. (INMB) is a publicly traded company on the Nasdaq, categorized under SIC 2836 (Biological Products, (No Diagnostic Substances)). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: INMB
CIK: 1711754
Exchange: Nasdaq
SIC 2836: Biological Products, (No Diagnostic Substances)
Fiscal Year End: 12/31
State: NV
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
CBIZ CPAs P.C.
Auditor SinceSince 12/31/2025 12:00:00 AM
Lead Engagement PartnerMohammed Asaduzzaman
Audit LocationHouston, Texas, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 4 | 2026-09-23 | 2026-09-15 | 4 Filing | 0001213900-26-102342 | View SEC Doc Filr Page |
| 3 | 2026-09-23 | 2026-09-08 | 3 Filing | 0001213900-26-102340 | View SEC Doc Filr Page |
| 4 | 2026-09-17 | 2026-09-15 | OWNERSHIP DOCUMENT | 0001213900-26-100877 | View SEC Doc Filr Page |
| 3 | 2026-09-16 | 2026-09-08 | OWNERSHIP DOCUMENT | 0001213900-26-100650 | View SEC Doc Filr Page |
| 8-K | 2026-09-14 | 2026-09-08 | CURRENT REPORT | 0001213900-26-099700 | View SEC Doc Filr Page |
| 10-Q | 2026-08-06 | 2026-06-30 | QUARTERLY REPORT | 0001213900-26-086135 | View SEC Doc Filr Page |
| 8-K | 2026-07-31 | 2026-07-31 | CURRENT REPORT | 0001213900-26-083961 | View SEC Doc Filr Page |
| 4 | 2026-07-07 | 2026-07-02 | 4 Filing | 0001213900-26-075738 | View SEC Doc Filr Page |
| 4 | 2026-07-07 | 2026-07-02 | 4 Filing | 0001213900-26-075737 | View SEC Doc Filr Page |
| 4 | 2026-07-07 | 2026-07-02 | 4 Filing | 0001213900-26-075736 | View SEC Doc Filr Page |
| 8-K | 2026-07-01 | 2026-06-30 | CURRENT REPORT | 0001213900-26-073983 | View SEC Doc Filr Page |
| 8-K | 2026-06-23 | 2026-06-23 | CURRENT REPORT | 0001213900-26-071082 | View SEC Doc Filr Page |
| 8-K | 2026-06-17 | 2026-06-16 | CURRENT REPORT | 0001213900-26-069611 | View SEC Doc Filr Page |
| 8-K | 2026-06-02 | 2026-06-02 | CURRENT REPORT | 0001213900-26-064144 | View SEC Doc Filr Page |
| 8-K | 2026-05-14 | 2026-05-14 | CURRENT REPORT | 0001213900-26-056599 | View SEC Doc Filr Page |
| 10-Q | 2026-05-07 | 2026-03-31 | QUARTERLY REPORT | 0001213900-26-053338 | View SEC Doc Filr Page |
| 8-K | 2026-05-05 | 2026-04-29 | CURRENT REPORT | 0001213900-26-052231 | View SEC Doc Filr Page |
| DEF 14A | 2026-04-23 | 2026-06-16 | PROXY STATEMENT | 0001213900-26-047080 | View SEC Doc Filr Page |
| 10-K | 2026-03-30 | 2025-12-31 | ANNUAL REPORT | 0001213900-26-036370 | View SEC Doc Filr Page |
| 8-K | 2026-02-27 | 2026-02-27 | CURRENT REPORT | 0001213900-26-021120 | View SEC Doc Filr Page |
| 8-K | 2026-02-23 | 2026-02-23 | CURRENT REPORT | 0001213900-26-019321 | View SEC Doc Filr Page |
| 8-K | 2026-02-19 | 2026-02-19 | CURRENT REPORT | 0001213900-26-018396 | View SEC Doc Filr Page |
| 8-K | 2026-02-13 | 2026-02-10 | CURRENT REPORT | 0001213900-26-016385 | View SEC Doc Filr Page |
| 8-K | 2026-01-27 | 2026-01-27 | CURRENT REPORT | 0001213900-26-008204 | View SEC Doc Filr Page |
| 8-K | 2025-12-23 | 2025-12-22 | CURRENT REPORT | 0001213900-25-125282 | View SEC Doc Filr Page |